NSAIDs and fracture healing

Current Opinion in Rheumatology

Volumn 25, Issue 4, 2013, Pages 524-531

  Geusens, Piet ^a,b,c   Emans, Pieter J ^a,b   De Jong, Joost J A ^a,b   Van Den Bergh, Joop ^a,b,c,d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c HASSELT UNIVERSITY   (Belgium)

^d VIECURI MEDICAL CENTER   (Netherlands)

Author keywords

cyclo oxygenase inhibitors; cyclo oxygenases 1; cyclo oxygenases 2; fracture healing; inflammation; prostaglandins

Indexed keywords

3 (3 FLUOROPHENYL) 5,5 DIMETHYL 4 (4 METHYLSULFONYLPHENYL) 2(5H) FURANONE; ARACHIDONIC ACID; BONE MORPHOGENETIC PROTEIN 2; CELECOXIB; CHEMOKINE; COLECALCIFEROL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FIBROBLAST GROWTH FACTOR 2; GLUCOCORTICOID; GROWTH FACTOR; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; KETOPROFEN; KETOROLAC; MELOXICAM; MEMBRANE PHOSPHOLIPID; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARECOXIB; PIROXICAM; PROSTAGLANDIN; ROFECOXIB; TENOXICAM; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; COMORBIDITY; DRUG BINDING; ENCHONDRAL OSSIFICATION; FRACTURE; FRACTURE HEALING; HUMAN; INFLAMMATION; LIFESTYLE; MALNUTRITION; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; FRACTURE HEALING; FRACTURES, BONE; HUMANS; RISK FACTORS;

EID: 84879887279     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32836200b8     Document Type: Review

References (85)

1. Grohs JG, Schmidt M, Wanivenhaus A. Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up. Acta Orthop 2007; 78:95-98. (Pubitemid 46570264)
2. Sudmann E, Dregelid E, Bessesen A, Morland J. Inhibition of fracture healing by indomethacin in rats. Eur J Clin Invest 1979; 9:333-339. (Pubitemid 10142421)
3. Butcher CK, Marsh DR. Nonsteroidal anti-inflammatory drugs delay tibial fracture union. Injury 1996; 27:375.
4. Blackwell KA, Raisz LG, Pilbeam CC. Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab 2010; 21:294-301.
5. Kronenberg HM. Developmental regulation of the growth plate. Nature 2003; 423:332-336. (Pubitemid 40852707)
6. Mackie EJ, Ahmed YA, Tatarczuch L, et al. Endochondral ossification: how cartilage is converted into bone in the developing skeleton. Int J Biochem Cell Biol 2008; 40:46-62. (Pubitemid 350052658)
7. Welting TJ, Caron MM, Emans PJ, et al. Inhibition of cyclooxygenase-2 impacts chondrocyte hypertrophic differentiation during endochondral ossification. Eur Cell Mater 2011; 22:420-436.
8. Bhandari M, Tornetta P 3rd, Sprague S, et al. Predictors of reoperation following operative management of fractures of the tibial shaft. J Orthop Trauma 2003; 17:353-361. (Pubitemid 36701599)
9. Hernandez RK, Do TP, Critchlow CW, et al. Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. Acta Orthopaedica 2012; 83:653-660.
10. Robertson G, Xie C, Chen D, et al. Alteration of femoral bone morphology and density in COX-2-/- mice. Bone 2006; 39:767-772. (Pubitemid 44311722)
11. Einhorn TA, Majeska RJ, Rush EB, et al. The expression of cytokine activity by fracture callus. J Bone Miner Res 1995; 10:1272-1281.
12. Gerstenfeld LC, Cullinane DM, Barnes GL, et al. Fracture healing as a postnatal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 2003; 88:873-884. (Pubitemid 36337032)
13. Mountziaris PM, Mikos AG. Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng Part B Rev 2008; 14:179-186. (Pubitemid 351839215)
14. Rundle CH, Wang H, Yu H, et al. Microarray analysis of gene expression during the inflammation and endochondral bone formation stages of rat femur fracture repair. Bone 2006; 38:521-529.
15. Caron MM, Emans PJ, Surtel DA, et al. Activation of NF-kappaB/p65 facilitates early chondrogenic differentiation during endochondral ossification. PloS One 2012; 7:e33467.
16. Dekel S, Lenthall G, Francis MJ. Release of prostaglandins from bone and muscle after tibial fracture: an experimental study in rabbits. J Bone Joint Surg Br 1981; 63B:185-189. (Pubitemid 11098763)
17. Ke HZ, Jee WS, Mori S, et al. Effects of long-term daily administration of prostaglandin-E2 on maintaining elevated proximal tibial metaphyseal cancellous bone mass in male rats. Calcif Tissue Int 1992; 50:245-252.
18. Keller J, Klamer A, Bak B, Suder P. Effect of local prostaglandin E2 on fracture callus in rabbits. Acta Orthop Scand 1993; 64:59-63. (Pubitemid 23092305)
19. Brochhausen C, Neuland P, Kirkpatrick CJ, et al. Cyclooxygenases and prostaglandin E2 receptors in growth plate chondrocytes in vitro and in situ:prostaglandin E2 dependent proliferation of growth plate chondrocytes. Arthritis Res Ther 2006; 8:R78.
20. Zhang X, Schwarz EM, Young DA, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109:1405-1415. (Pubitemid 34596166)
21. Naik AA, Xie C, Zuscik MJ, et al. Reduced COX-2 expression in aged mice is associated with impaired fracture healing. J Bone Miner Res 2009; 24:251-264.
22. Arikawa T, Omura K, Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol 2004; 200:400-406. (Pubitemid 39006932)
23. Paralkar VM, Grasser WA, Mansolf AL, et al. Regulation of BMP-7 expression by retinoic acid and prostaglandin E(2). J Cell Physiol 2002; 190:207-217. (Pubitemid 34027823)
24. Knippenberg M, Helder MN, Zandieh Doulabi B, et al. Osteogenesis versus chondrogenesis by BMP-2 and BMP-7 in adipose stem cells. Biochem Biophys Res Commun 2006; 342:902-908. (Pubitemid 43320483)
25. Spiro AS, Beil FT, Baranowsky A, et al. BMP-7-induced ectopic bone formation and fracture healing is impaired by systemic NSAID application in C57BL/6-mice. J Orthop Res 2010; 28:785-791.
26. Gerstenfeld LC, Thiede M, Seibert K, et al. Differential inhibition of fracture healing by nonselective and cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs. J Orthop Res 2003; 21:670-675. (Pubitemid 36763489)
27. Dimmen S, Nordsletten L, Madsen JE. Parecoxib and indomethacin delay early fracture healing: a study in rats. Clin Orthop Relat Res 2009; 467:1992-1999.
28. Karachalios T, Boursinos L, Poultsides L, et al. The effects of the short-term administration of low therapeutic doses of anti-COX-2 agents on the healing of fractures. An experimental study in rabbits. J Bone Joint Surg Br 2007; 89:1253-1260. (Pubitemid 350057968)
29. Goodman SB, Ma T, Mitsunaga L, et al. Temporal effects of a COX-2-selective NSAID on bone ingrowth. J Biomed Mater Res A 2005; 72:279-287. (Pubitemid 40270998)
30. Long J, Lewis S, Kuklo T, et al. The effect of cyclooxygenase-2 inhibitors on spinal fusion. J Bone Joint Surg Am 2002; 84-A:1763-1768. (Pubitemid 35176467)
31. Brown KM, Saunders MM, Kirsch T, et al. Effect of COX-2-specific inhibition on fracture-healing in the rat femur. J Bone Joint Surg Am 2004; 86A:116-123. (Pubitemid 38057344)
32. Persson PE, Sisask G, Nilsson O. Indomethacin inhibits bone formation in inductive allografts but not in autografts: studies in rat. Acta Orthop 2005; 76:465-469. (Pubitemid 41232774)
33. Kidd LJ, Cowling NR, Wu AC, et al. Selective and nonselective cyclooxygenase inhibitors delay stress fracture healing in the rat ulna. J Orthop Res 2013; 31:235-242.
34. Sudmann E, Bang G. Indomethacin-induced inhibition of haversian remodelling in rabbits. Acta Orthop Scand 1979; 50:621-627. (Pubitemid 10162502)
35. Giordano V, Giordano M, Knackfuss IG, et al. Effect of tenoxicam on fracture healing in rat tibiae. Injury 2003; 34:85-94. (Pubitemid 36143629)
36. Riew KD, Long J, Rhee J, et al. Time-dependent inhibitory effects of indomethacin on spinal fusion. J Bone Joint Surg Am 2003; 85A:632-634. (Pubitemid 36538710)
37. Endo K, Sairyo K, Komatsubara S, et al. Cyclooxygenase-2 inhibitor delays fracture healing in rats. Acta Orthop 2005; 76:470-474. (Pubitemid 41232775)
38. Krischak GD, Augat P, Sorg T, et al. Effects of diclofenac on periosteal callus maturation in osteotomy healing in an animal model. ArchOrthop Trauma Surg 2007; 127:3-9. (Pubitemid 44964028)
39. Leonelli SM, Goldberg BA, Safanda J, et al. Effects of a cyclooxygenase-2 inhibitor (rofecoxib) on bone healing. Am J Orthop (Belle Mead NJ) 2006; 35:79-84.
40. O'Connor JP, Capo JT, Tan V, et al. A comparison of the effects of ibuprofen and rofecoxib on rabbit fibula osteotomy healing. Acta Orthop 2009; 80: 597-605.
41. Herbenick MA, Sprott D, Stills H, Lawless M. Effects of a cyclooxygenase 2 inhibitor on fracture healing in a rat model. Am J Orthop (Belle Mead NJ) 2008; 37:E133-E137.
42. Matsumoto MA, De Oliveira A, Ribeiro Junior PD, et al. Short-term administration of nonselective and selective COX-2 NSAIDs do not interfere with bone repair in rats. J Mol Histol 2008; 39:381-387.
43. Akritopoulos P, Papaioannidou P, Hatzokos I, et al. Parecoxib has nonsignificant long-term effects on bone healing in rats when administered for a short period after fracture. Arch Orthop Trauma Surg 2009; 129:1427-1432.
44. Utvag SE, Fuskevag OM, Shegarfi H, Reikeras O. Short-term treatment with COX-2 inhibitors does not impair fracture healing. J Invest Surg 2010; 23:257-261.
45. Hak DJ, Schulz KS, Khoie B, Hazelwood SJ. The effect of Cox-2 specific inhibition on direct fracture healing in the rabbit tibia. J Orthop Sci 2011; 16:93-98.
46. Wurnig C, Schwameis E, Bitzan P, Kainberger F. Six-year results of a cementless stem with prophylaxis against heterotopic bone. Clin Orthop Relat Res 1999; 8:150-158. (Pubitemid 29169804)
47. Davis TR, Ackroyd CE. Nonsteroidal anti-inflammatory agents in the management of Colles' fractures. Br J Clin Pract 1988; 42:184-189.
48. Adolphson P, Abbaszadegan H, Jonsson U, et al. No effects of piroxicam on osteopenia and recovery after Colles' fracture. A randomized, double-blind, placebo-controlled, prospective trial. Arch Orthop Trauma Surg 1993; 112:127-130. (Pubitemid 23194371)
49. Sculean A, Berakdar M, Donos N, et al. The effect of postsurgical administration of a selective cyclo-oxygenase-2 inhibitor on the healing of intrabony defects following treatment with enamel matrix proteins. Clin Oral Invest 2003; 7:108-112.
50. Meunier A, Aspenberg P, Good L. Celecoxib does not appear to affect prosthesis fixation in total knee replacement: a randomized study using radiostereometry in 50 patients. Acta Orthop 2009; 80:46-50.
51. Vitale MG, Choe JC, Hwang MW, et al. Use of ketorolac tromethamine in children undergoing scoliosis surgery. an analysis of complications. Spine J 2003; 3:55-62. (Pubitemid 38351773)
52. Pradhan BB, Tatsumi RL,Gallina J, et al. Ketorolac and spinal fusion: does the perioperative use of ketorolac really inhibit spinal fusion? Spine (Phila Pa 1976) 2008; 33:2079-2082.
53. Sucato DJ, Lovejoy JF, Agrawal S, et al. Postoperative ketorolac does not predispose to pseudoarthrosis following posterior spinal fusion and instrumentation for adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2008; 33:1119-1124. (Pubitemid 351630223)
54. Horn PL, Wrona S, Beebe AC, Klamar JE. A retrospective quality improvement study of ketorolac use following spinal fusion in pediatric patients. Orthop Nurs 2010; 29:342-343.
55. Glassman SD, Rose SM, Dimar JR, et al. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine (Phila Pa 1976) 1998; 23:834-838. (Pubitemid 28169215)
56. Deguchi M, Rapoff AJ, Zdeblick TA. Posterolateral fusion for isthmic spondylolisthesis in adults: analysis of fusion rate and clinical results. J Spinal Disord 1998; 11:459-464. (Pubitemid 29024381)
57. Giannoudis PV, MacDonald DA, Matthews SJ, et al. Nonunion of the femoral diaphysis. The influence of reaming and nonsteroidal anti-inflammatory drugs. J Bone Joint Surg Br 2000; 82:655-658.
58. Park SY, Moon SH, Park MS, et al. The effects of ketorolac injected via patient controlled analgesia postoperatively on spinal fusion. Yonsei Med J 2005; 46:245-251.
59. Bhattacharyya T, Levin R, Vrahas MS, Solomon DH. Nonsteroidal antiinflammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum 2005; 53:364-367. (Pubitemid 40799874)
60. Lumawig JM, Yamazaki A, Watanabe K. Dose-dependent inhibition of diclofenac sodium on posterior lumbar interbody fusion rates. Spine J 2009; 9:343-349.
61. Burd TA, Hughes MS, Anglen JO. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br 2003; 85:700-705. (Pubitemid 36927035)
62. Dumont AS, Verma S, Dumont RJ, Hurlbert RJ. Nonsteroidal anti-inflammatory drugs and bone metabolism in spinal fusion surgery: a pharmacological quandary. J Pharmacol Toxicol Methods 2000; 43:31-39.
63. Einhorn TA. Cox-2: where are we in 2003? the role of cyclooxygenase-2 in bone repair. Arthritis Res Ther 2003; 5:5-7. (Pubitemid 36849743)
64. Clarke S, Lecky F. Best evidence topic report. Do nonsteroidal anti-inflammatory drugs cause a delay in fracture healing? Emerg Med J 2005; 22:652-653.
65. Thaller J, Walker M, Kline AJ, Anderson DG. The effect of nonsteroidal antiinflammatory agents on spinal fusion. Orthopedics 2005; 28:299-303. (Pubitemid 40425858)
66. Gaston MS, Simpson AH. Inhibition of fracture healing. J Bone Joint Surg Br 2007; 89:1553-1560. (Pubitemid 351183403)
67. Vuolteenaho K,Moilanen T, Moilanen E. Nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin Pharmacol Toxicol 2008; 102:10-14. (Pubitemid 350294081)
68. O'Connor JP, Lysz T. Celecoxib, NSAIDs and the skeleton. Drugs Today 2008; 44:693-709.
69. Pountos I, Georgouli T, Blokhuis TJ, et al. Pharmacological agents and impairment of fracture healing: what is the evidence? Injury 2008; 39: 384-394.
70. Xian CJ, Zhou XF. Treating skeletal pain: limitations of conventional antiinflammatory drugs, and antineurotrophic factor as a possible alternative. Nat Clin Pract Rheumatol 2009; 5:92-98.
71. Boursinos LA, Karachalios T, Poultsides L, Malizos KN. Do steroids, conventional nonsteroidal anti-inflammatory drugs and selective Cox-2 inhibitors adversely affect fracture healing? J Musculoskeletal Neuronal Interact 2009; 9:44-52.
72. Pountos I, Georgouli T, Calori GM, Giannoudis PV. Do nonsteroidal antiinflammatory drugs affect bone healing? A critical analysis. Scientific World Journal 2012; 2012:606404.
73. Kurmis AP, Kurmis TP, O'Brien JX, Dalén T. The effect of nonsteroidal antiinflammatory drug administration on acute phase fracture-healing: a review. J Bone Joint Surg 2012; 94:815-823.
74. Dodwell ER, Latorre JG, Parisini E, et al. NSAID exposure and risk of nonunion: a meta-analysis of case-control and cohort studies. Calcif Tissue Int 2010; 87:193-202.
75. Bauer DC, Orwoll ES, Fox KM, et al. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. J Bone Miner Res 1996; 11:29-35. (Pubitemid 26026741)
76. Carbone LD, Tylavsky FA, Cauley JA, et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res 2003; 18:1795-1802. (Pubitemid 37322557)
77. van Staa TP, Leufkens HG, Cooper C. Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone 2000; 27:563-568.
78. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int 2006; 79:84-94. (Pubitemid 44306165)
79. Vestergaard P, Hermann P, Jensen JE, et al. Effects of paracetamol, nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int 2012; 23:1255-1265.
80. Hegeman J, van den Bemt BJ, Duysens J, van Limbeek J. NSAIDs and the risk of accidental falls in the elderly: a systematic review. Drug Saf 2009; 32:489-498.
81. Hegeman J, Nienhuis B, van den Bemt B, et al. The effect of a nonsteroidal anti-inflammatory drug on two important predictors for accidental falls: postural balance and manual reaction time: a randomized, controlled pilot study. Hum Mov Sci 2011; 30:384-395.
82. Vosse D, Landewe R, van der Heijde D, et al. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 2009; 68:1839-1842.
83. Jacobs WB, Fehlings MG. Ankylosing spondylitis and spinal cord injury: origin, incidence, management, and avoidance. Neurosurg Focus 2008; 24:E12.
84. Vosse D, van der Heijde D, Landewe R, et al. Determinants of hyperkyphosis in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65:770-774. (Pubitemid 43803770)
85. Kroon F, LandewéR, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012; 71:1623-1629.